Getting to the point in IBS

How patient-focused endpoints could expand the number of patients taking Linzess

A large epidemiological study set Ironwood Pharmaceuticals Inc. on a path to finding symptomatic outcomes important to IBS-C patients. The company’s new Phase IIIb study of Linzess linaclotide will probe those outcomes, seeking results that could change how doctors and patients think about treatment goals.

Linzess was approved in 2012 to treat constipation-predominant irritable bowel syndrome (IBS-C) based on improvements in abdominal pain and constipation.

The new trial, announced on July 16, will test how well the peptide guanylate cyclase C (GCC; GUCY2C) agonist improves the abdominal symptoms of bloating, pain and discomfort vs. placebo.

Chief Commercial Officer and SVP of Marketing and Sales Thomas McCourt said people with IBS-C may talk to their doctors about constipation most because it is a consistent

Read the full 1208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers